With groundbreaking approval, Amgen launches new class of medicine for migraine patients

Amgen (NSDQ:AMGN) won FDA approval this week for its once-monthly Aimovig injection designed to prevent the onset of migraines in adults.

The drug is the first of its kind – a molecule that blocks the receptor for a protein that is linked to migraine pain, the calcitronin gene-related peptide. Other major pharmaceutical companies like Eli Lilly (NYSE:LLY) and Teva Pharmaceuticals (NYSE:TEVA) are working on their own CGRP product, but Amgen’s is the first to hit the market.

Get the full story at our sister site, Drug Delivery News.

The post With groundbreaking approval, Amgen launches new class of medicine for migraine patients appeared first on MassDevice.

from MassDevice https://ift.tt/2rQ6mqj